Bortezomib retreatment in relapsed multiple myeloma-results from a retrospective multicentre survey in Germany and Switzerland

Oncology

Volumn 79, Issue 3-4, 2011, Pages 247-254

  Hrusovsky, I ^a   Emmerich, B ^b   Von Rohr, A ^e   Voegeli, J ^f   Taverna, C ^g   Olie, R A ^h   Pliskat, H ^c   Frohn, C ^c   Hess, G ^d  

^a Diakonie Krankenhaus   (Germany)

^b Oncological Practice   (Germany)

^c JANSSEN CILAG GMBH   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e Onkozentrum Hirslanden   (Switzerland)

^f Oncology Practice   (Switzerland)

^g KANTONSSPITAL   (Switzerland)

^h Cilag AG   (Switzerland)

Author keywords

Bortezomib; Multiple myeloma; Relapsed; Retreatment

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GASTROINTESTINAL AGENT; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GERMANY; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; HYPESTHESIA; LUNG EDEMA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; NEUROPATHY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; RETREATMENT; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SEPSIS; STAPHYLOCOCCAL BACTEREMIA; SWITZERLAND; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; REMISSION INDUCTION; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME;

EID: 79952105543     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322866     Document Type: Article

References (19)

1. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR: Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874 (Pubitemid 38879952)
2. β (bortezomib) for Injection. Pre-scribing Information. Cambridge, Millen-nium Pharmaceuticals, Inc., 2009.
3. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC: Extended follow-up of a phase 3 trial in relapsed mul-tiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557-3560. (Pubitemid 350159621)
4. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA: An observational, retro-spective analysis of retreatment with borte-zomib for multiple myeloma. Clin Lympho-ma Myeloma 2008; 8:140-145.
5. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS: Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008; 6: 755-760.
6. Petrucci MT, Blau IW, Corradini P, Dimo-poulos MA, Drach J, Giraldo P, Teixeira A, Blade J: Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study. Haematologica 2010; 95: 377a.
7. TM. Multiple Myeloma (V.1.2011). Fort Washington, NCCN; 2010.
8. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI: The growth fraction of human myeloma cells. Blood 1981; 57: 333-338. (Pubitemid 11174896)
9. Richardson PG, Barlogie B, Berenson J, Sing-hal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, re-fractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
10. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA: Frequency characteristics, and reversibility of periph-eral neuropathy during treatment of ad-vanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-3120. (Pubitemid 46638949)
11. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498. (Pubitemid 41007864)
12. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos M-V, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG: Bortezomib plus melphalan and prednisone for initial treat-ment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
13. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC: Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bor-tezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008; 143: 537-540.
14. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San MJ: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in re-lapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144: 895-903.
15. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdul-kadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF: Bortezomib plus melphalan and predni-sone compared with melphalan and predni-sone in previously untreated multiple myelo-ma: updated follow-up and impact of subse-quent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259-2266.
16. Lonial S, Richardson PG, San MJ, Sonneveld P, Schuster MW, Blade J, Cavenagh J, Rajku-mar SV, Jakubowiak AJ, Esseltine DL, An-derson KC, Harousseau JL: Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008; 143:222-229.
17. Lonial S, Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Goldschmidt H, Reece D, San M J, Blade J, Boccadoro M, Cavenagh J, Dalton W, Boral A, Schenkein D, Anderson KC: Hematologic profiles in the phase 3 APEX trial. Blood 2005; 106:970a.
18. Ciolli S, Leoni F, Casini C, Bosi A: Feasibility and efficacy of bortezomib re-treatment in multiple myeloma. Haematologica 2007; 92: 260a.
19. Rubio-Martinez A, Recasens V, Soria B, Montanes MA, Rubio-Escuin R, Giraldo P: Response to retreatment on relapse multiple myeloma patients previously treated with bortezomib. Haematologica 2008; 93: 649a.